TY - JOUR AB - Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare CD30+ lymphoproliferative disorder characterized by the development of lesions ranging from papules to large tumors. Most cases present as localized disease, however multifocal and generalized involvement of the skin can occur. Several treatments have been proposed for PCALCL; however a highly effective standard approach to multifocal disease has not yet been elucidated. The disease expression of CD30 antigen in at least 75% of the tumor makes it an optimal target for immunotherapy. The current study presents a case of a 62‑year‑old male referred to the University of Padua Dermatology Clinic complaining about nodular and ulcerated lesions involving the frontal area and scalp that were 8 cm in diameter. Doses of 180 mg brentuximab vedotin (BV), which is an antibody drug conjugate binding CD30 antigen, were administered every 21 days. A 75% decrease in dimensions after the first infusion and a complete remission after the second was observed. Disease response appeared to be dose‑related and adverse reactions, in particular peripheral neuropathy, may be an effect of cumulative toxicity, meaning that treatment cycle reduction should be considered. Based on the present results, A high dose, short course of BV is recommended as a cost‑effective approach for PCALCL. However, further studies are required to assess the efficacy and other potential advantages of this therapeutic regimen. AD - Unit of Dermatology, University of Padua, Padova I‑35128, Italy Unit of Medical Oncology 1, Veneto Institute of Oncology IOV‑IRCCS, Padova I‑35128, Italy AU - Milan,Elisa AU - Miceli,Paola AU - Sernicola,Alvise AU - Finotto,Silvia AU - Marino,Dario AU - Alaibac,Mauro DA - 2021/06/01 DO - 10.3892/mco.2021.2283 IS - 6 JO - Mol Clin Oncol KW - lymphoproliferative disorder CD30 brentuximab vedotin primary cutaneous anaplastic large cell lymphoma immunotherapy PY - 2021 SN - 2049-9450 2049-9469 SP - 121 ST - Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin T2 - Molecular and Clinical Oncology TI - Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin UR - https://doi.org/10.3892/mco.2021.2283 VL - 14 ER -